A “high risk drug” doesn’t really make it to phase 3 clinical trials with hundreds of patients when there is a standard of care does it? I’d suggest you go and read the P2 results presentation slowly to see the benefits. Even marginal improvements in reducing protein urea can reduce total time people are on dialysis and extend the time that a healthy kidney lasts.
You are falling back to the “if it’s slightly better is it worth it” and the response is the DSMB would say yes.
A “high risk drug” doesn’t really make it to phase 3 clinical...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $186.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $500.6K | 1.496M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24738 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 158051 | 4 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
34.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 33.0¢ | 34.0¢ | 33.0¢ | 742597 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| DXB (ASX) Chart |